CERC 611

Drug Profile

CERC 611

Alternative Names: (-)-25 LY3130481; CERC-611; LY-3130481

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Cerecor
  • Class Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epilepsy

Most Recent Events

  • 14 Mar 2017 Cerecor has patent pending for composition of matter and use claims of varying scope for additional selective TARP γ-8-dependent AMPA receptor antagonists in USA and World
  • 14 Mar 2017 Cerecor has patent protection for composition of matter and use claims for CERC 611 in USA and World
  • 27 Sep 2016 Cerecor plans to file an IND application with the US FDA in for Epilepsy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top